Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): A randomised, controlled, open-label, phase 3 trial

Jeffrey S. Weber, Sandra P. D'Angelo, David Minor, F. Stephen Hodi, Ralf Gutzmer, Bart Neyns, Christoph Hoeller, Nikhil I. Khushalani, Wilson H. Miller, Christopher D. Lao, Gerald P. Linette, Luc Thomas, Paul Lorigan, Kenneth F. Grossmann, Jessica C. Hassel, Michele Maio, Mario Sznol, Paolo A. Ascierto, Peter Mohr, Bartosz ChmielowskiAlan Bryce, Inge M. Svane, Jean Jacques Grob, Angela M. Krackhardt, Christine Horak, Alexandre Lambert, Arvin S. Yang, James Larkin

Research output: Contribution to journal › Article › peer-review

1673 Scopus citations

Fingerprint

Dive into the research topics of 'Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): A randomised, controlled, open-label, phase 3 trial'. Together they form a unique fingerprint.

Medicine & Life Sciences